Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents
2002 (English)In: Bioconjugate chemistry, ISSN 1043-1802, E-ISSN 1520-4812, Vol. 13, no 4, 737-743 p.Article in journal (Refereed) Published
Liposomes are of interest as drug delivery tools for therapy of cancer and infectious diseases. We investigated conjugation of epidermal growth factor, EGF, to liposomes using the micelle-transfer method. EGF was conjugated to the distal end of PEG−DSPE lipid molecules in a micellar solution and the EGF−PEG−DSPE lipids were then transferred to preformed liposomes, either empty or containing the DNA-binding compound, water soluble acridine, WSA. We found that the optimal transfer conditions were a 1-h incubation at 60 °C. The final conjugate, 125I-EGF−liposome−WSA, contained approximately 5 mol % PEG, 10−15 EGF molecules at the liposome surface, and 104 to 105 encapsulated WSA molecules could be loaded. The conjugate was shown to have EGF-receptor-specific cellular binding in cultured human glioma cells.
Place, publisher, year, edition, pages
2002. Vol. 13, no 4, 737-743 p.
IdentifiersURN: urn:nbn:se:uu:diva-90321DOI: 10.1021/bc0100713OAI: oai:DiVA.org:uu-90321DiVA: diva2:162631